Russell Szmulewitz to Benzamides
This is a "connection" page, showing publications Russell Szmulewitz has written about Benzamides.
Connection Strength
3.415
-
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
Score: 0.766
-
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol. 2026 May; 89(5):396-403.
Score: 0.215
-
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e258751.
Score: 0.204
-
Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2024 04 02; 23(4):552-563.
Score: 0.189
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 03 15; 30(6):1152-1159.
Score: 0.189
-
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2024 Aug; 7(4):860-869.
Score: 0.185
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247.
Score: 0.167
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
Score: 0.165
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282.
Score: 0.158
-
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088.
Score: 0.154
-
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 04 20; 39(12):1371-1382.
Score: 0.153
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2021 May; 205(5):1361-1371.
Score: 0.151
-
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614.
Score: 0.144
-
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. Mol Cancer Ther. 2017 08; 16(8):1680-1692.
Score: 0.117
-
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89.
Score: 0.094
-
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. Clin Cancer Res. 2026 May 15; 32(10):1973-1982.
Score: 0.055
-
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Clin Cancer Res. 2023 05 15; 29(10):1929-1937.
Score: 0.045
-
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241.
Score: 0.044
-
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622.
Score: 0.041
-
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021 06; 150:83-94.
Score: 0.039
-
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 11 10; 37(32):2974-2986.
Score: 0.034
-
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol. 2019 05 01; 37(13):1120-1129.
Score: 0.033
-
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget. 2016 May 03; 7(18):26259-74.
Score: 0.027
-
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate. 2014 Nov; 74(15):1530-43.
Score: 0.024
-
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013; 8(1):e53701.
Score: 0.022